

**NLM Citation:** Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Ruxolitinib.

[Updated 2018 Dec 3].


Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/



### **Ruxolitinib**

Revised: December 3, 2018.

CASRN: 941678-49-5



# **Drug Levels and Effects**

## **Summary of Use during Lactation**

No information is available on the clinical use of ruxolitinib during breastfeeding. Because ruxolitinib is 97% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during ruxolitinib therapy and for 2 weeks after the last dose.

#### **Drug Levels**

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

#### **Effects in Breastfed Infants**

Relevant published information was not found as of the revision date.

#### **Effects on Lactation and Breastmilk**

Relevant published information was not found as of the revision date.

## **Substance Identification**

#### **Substance Name**

Ruxolitinib

## **CAS Registry Number**

941678-49-5

### **Drug Class**

**Breast Feeding** 

Lactation

Antineoplastic Agents

**Enzyme Inhibitors** 

**Protein Kinase Inhibitors** 

Signal Transduction Inhibitors

Janus Kinase Inhibitors